Cue Biopharma, Inc.
Company Stats
- Market Cap
- $187.9M
- as of Sep 30, 2026
- Shares Outstanding
- 7.3M
- Free Float
- 57.8%
Income Statement
- Revenue
- $27.5M
- Operating Income
- -$26.6M
- Net Income
- -$26.6M
- EBITDA
- -$26.2M
- Revenue Growth, 3Y
- 180.5%
- FCF Margin, 3Y Avg
- -399.8%
- FCF Margin, Worst Year
- -727.9%
Cash Flow
- Free Cash Flow
- -$21.9M
- FCF Yield
- -11.6%
- Owner FCF Yield
- -14.2%
Balance Sheet
- Cash & Equivalents
- $27.1M
Returns & Capital
- SBC, 3Y Avg
- $6.6M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $27.5M | -$21.9M | -79.6% |
| FY2024 | $9.3M | -$36.4M | -391.9% |
| FY2023 | $5.5M | -$40.0M | -727.9% |
| FY2022 | $1.2M | -$42.0M | -3371.6% |
| FY2021 | $14.9M | -$39.8M | -266.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges